Genomic Profiling of Prostate Cancer: An Updated Review
Koji Hatano, Norio Nonomura
Abstract
shows a distinct pattern of genomic alterations, associating with better clinical outcomes. Several genomic profiling tests, which can be used in the clinic, are approved by the U.S. Food and Drug Administration, including MSK-IMPACT, FoundationOne CDx, and FoundationOne Liquid CDx. Here, we review emerging evidence for genomic profiling of prostate cancer, especially focusing on associations between genomic alteration and clinical outcome, liquid biopsy, and actionable molecular alterations.
Topics & Concepts
Prostate cancerPTENMedicineProstateLiquid biopsyPrecision medicineDiseaseCancerOncologyBioinformaticsInternal medicinePathologyBiologyPI3K/AKT/mTOR pathwayGeneticsSignal transductionProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentCancer Genomics and Diagnostics